BMJ · 2012 · 21 citations · 24 references
PharmacyInternal MedicinePharmacotherapyPulmonary Function TestingPulmonologyRespiratory PharmacotherapyBronchodilator TherapyChronic Obstructive Pulmonary DiseaseCombination Inhaler TherapyInhalation TherapyRespiratory DiseaseRespiratory MedicineChronic Obstructive Pulmonary Disease SpirometryInhaled Corticosteroid AdministrationInhaled Corticosteroid CombinationsInhaled TherapiesLong-acting Beta AgonistsLong-acting Beta2-agonistsLong-acting Bronchodilator TherapyLung Function Testing
A 65 year old female former smoker presents to your practice with gradually worsening shortness of breath while walking up a flight of stairs and a daily cough, productive of small amounts of white phlegm. She has a smoking history of 20 cigarettes a day for 20 years and chronic obstructive pulmonary disease (COPD). Her breathlessness had gradually worsened since an influenza-like illness six months ago, which was treated with a two week course of oral prednisolone and antibiotics. Since the illness she has used inhaled tiotropium 18 µg once daily and inhaled salbutamol as needed. Spirometry at the general practice shows a forced expiratory volume in one second (FEV1) of 63% predicted and a ratio of FEV1 to forced vital capacity of 0.65 after use of a bronchodilator. These values have not changed significantly over the previous year. As she is still symptomatic, her general practitioner recommends stopping tiotropium and starting a combination inhaler of a corticosteroid and a long acting β2 agonist. Inhaled corticosteroids are glucocorticoids that bind to the glucocorticoid receptors in the airways and cause a reduction in lung inflammation.1 They are taken via metered dose inhalers or dry powder inhalers. The most commonly used inhaled corticosteroids in COPD are fluticasone propionate, budesonide, and beclometasone dipropionate (table 1⇓). View this table: Table 1 Combinations of inhaled corticosteroids plus long acting β2 agonists for chronic obstructive pulmonary disease (COPD). Monotherapy with inhaled corticosteroids is not approved for the treatment of COPD The role of inhaled corticosteroids in COPD is controversial. However, on the basis of current evidence, using them as monotherapy cannot be recommended for most patients with this condition. The effect of such monotherapy in relieving dyspnoea and improving lung function is modest and weaker than that of long acting bronchodilators.2 Inhaled corticosteroids also …
24
Jadwiga A. Wedzicha, Peter M.A. Calverley, Terence Seemungal et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 843 citations